[[(2S,4S,5R)-5-(6-aminopurin-9-yl)-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: [[(2S,4S,5R)-5-(6-aminopurin-9-yl)-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
• 化学式: C₁₁H₁₈N₅O₁₁P₃
• 分子量: 489.21
• InChiKey: OXLFLXHBFRWUES-OKTBNZSVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.4
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  239
• 氢给体数：
  5
• 氢受体数：
  15

文献信息

• Amino acid phosphoramidate pronucleotides of 2′-cyano, azido and amino nucleosides for the treatment of HCV
  申请人：Centre National De La Recherche Scientifique

  公开号：US10231986B2

  公开（公告）日：2019-03-19

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.

  本文提供了用于治疗黄病毒科感染（包括 HCV 感染）的化合物、组合物和方法。在某些实施方案中，公开了核苷衍生物的化合物和组合物，可单独使用或与其他抗病毒药物联合使用。在某些实施方案中，化合物是根据式 1001 或 2001 的 2′-氰基、叠氮或氨基核苷： 或其药学上可接受的盐、溶液、立体异构体、同分异构体或多晶型，其中碱、W、R1 和 R2 如本文所述。
• 3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV
  申请人：Idenix Pharmaceuticals LLC

  公开号：EP2970358B1

  公开（公告）日：2021-06-30
• [EN] 3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV<br/>[FR] 3'-DÉSOXYNUCLÉOSIDES UTILISABLES EN VUE DU TRAITEMENT D'UNE INFECTION PAR LE VHC
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2014137926A1

  公开（公告）日：2014-09-12

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'- deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.